This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
FluMist - Refrigerated Formulation
Drug Names(s): Fluenz (EU), cold adapted intranasal influenza vaccine - trivalent, Liquid CAIV-T, Q-LAIV Flu Vac
Description: FluMist (Influenza Vaccine Live, Intranasal) is a live trivalent vaccine for administrationby intranasal spray. FluMist contains three vaccine virus strains: an A/H1N1 strain, an A/H3N2 strain and one B strain. The influenza virus strains in FluMst are (a) cold-adapted (ca) (i.e., they replicate efficiently at 25°C, a temperature that is restrictive for replication of many wild-type influenza viruses); (b) temperature sensitive (ts) (i.e., they are restricted in replication at 37°C (Type B strains) or 39°C (Type A strains), temperatures atwhichmanywild-type influenza viruses grow efficiently); and (c) attenuated(att)(i.e.,they do not produce classic influenza-like illness in the ferretmodel of human influenza infection).
Deal Structure: Liquid CAIV-T is being developed under a collaborative agreement between Wyeth and MedImmune.
In January 1999, the Company signed a worldwide collaborative agreement with Wyeth Lederle Vaccines, a subsidiary of Wyeth, for the development, manufacture, distribution, marketing, promotion, and sale of live, attenuated, cold adapted, nasally delivered influenza vaccines (flu vaccines). Under this agreement, Wyeth has exclusive worldwide rights to market the flu vaccines, excluding Korea, Australia, New Zealand and some South Pacific countries. The two companies will co-promote the flu vaccines in the United States. Wyeth holds the marketing rights for an initial term of seven years from the first commercial sale of the flu vaccines in the U.S. and an initial term of eight years from the first commercial sale of the flu vaccines outside the United States. Wyeth also has an option to extend its rights in the U.S. for an additional four years and to extend its international rights for an...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
FluMist - Refrigerated Formulation News
Pink Sheet MedImmune refrigerated FluMist clears FDA
Pink Sheet MedImmune next-generation FluMist
Pink Sheet Weekly Trademark Review Oct. 18, 2016
Additional information available to subscribers only: